Close Menu

NEW YORK – Revel Health and Coriell Life Sciences (CLS) said on Tuesday that they have partnered to help Medicare Advantage members take advantage of DNA testing to determine prescription drug efficacy.

Using Revel Connect, Revel Health's health action platform, the partners will communicate and promote CLS's genetic testing offering to Medicare Advantage members. Revel Health and CLS launched the first wave of the program in June to reach more than 22,000 members.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.